VivoSim Labs (VIVS) Non-Current Assets (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Non-Current Assets of $786000.0 for Q1 2026, down 68.8% year-over-year from $2.5 million in Q1 2025, and down 14.47% quarter-over-quarter from $919000.0 in Q4 2025.
VivoSim Labs (VIVS) Non-Current Assets (2011 - 2026) Analysis & Trends
VivoSim Labs' Non-Current Assets history runs 16 years deep, the most recent figure standing at $786000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 68.8% year-over-year to $786000.0; the TTM figure through Mar 2026 stood at $6.1 million (down 27.57% YoY), while the FY2026 annual figure was $786000.0, down 68.8% from the prior year.
- Non-Current Assets for Q1 2026 stood at $786000.0, down from $919000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $3.8 million in Q1 2022, with the low at -$5.3 million in Q2 2023.
- The 5-year median for Non-Current Assets is $2.4 million (2024), against an average of $2.0 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets jumped 147.73% in 2022, then plunged 246.99% in 2023.
- VivoSim Labs' Non-Current Assets stood at $3.5 million in 2022, then dropped by 23.81% to $2.6 million in 2023, then tumbled by 33.94% to $1.7 million in 2024, then sank by 47.31% to $919000.0 in 2025, then declined by 14.47% to $786000.0 in 2026.
- Business Quant data shows VIVS's Non-Current Assets at $786000.0 in Q1 2026, $919000.0 in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | 621,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 621,000.00 |
| Mar 31, 2026 | 786,000.00 |
| Dec 31, 2025 | 919,000.00 |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.52 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Jun 30, 2024 | 2.19 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | 2.64 Mn |
| Sep 30, 2023 | 2.87 Mn |
| Jun 30, 2023 | -5.35 Mn |
| Mar 31, 2023 | 3.27 Mn |
| Dec 31, 2022 | 3.47 Mn |
| Sep 30, 2022 | 3.55 Mn |
| Jun 30, 2022 | 3.64 Mn |
| Mar 31, 2022 | 3.76 Mn |
| Dec 31, 2021 | 3.92 Mn |
| Sep 30, 2021 | 1.58 Mn |